Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BackgroundTransmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a complement...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-07-01
Edice:	Frontiers in Immunology
Témata:	Pfs25 malaria transmission-blocking IMX313 vaccine
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!